It is made available under a CC-BY 4.0 International license .

1	Association of IFNAR2 rs2236757 and OAS3 rs10735079 polymorphisms with
2	susceptibility to COVID-19 infection and severity
3	
4	
5	
6	Mohammad Abdelhafez ¹ Abedelmaieed Nasereddin ² Omar Abu Shamma ¹ Raiaa Abed ¹
7	Raghida Sinnokrot ¹ , Omar Marof ¹ , Tarig Heif ¹ , Zaid Erekat ¹ , Amer Al-Jawabreh ³ , Suheir
8	Eregat ² *
9	1
10	
11	¹ Faculty of Medicine, Al-Quds University, Abu Deis, East Jerusalem, Palestine.
12	
13	² Biochemistry and Molecular Biology Department, Faculty of Medicine, Al-Quds University,
14	Abu Deis, East Jerusalem, Palestine.
15	
16	³ Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Arab American
17	University, Jenin, Palestine.
18	
19	
20	
21	*Corresponding Author: Suheir Ereqat <u>sereqat(a)staff.alquds.edu</u>
22	
23 74	
2 4 25	
26	Running title . Human genetic factors in COVID-19
27	
28	
29	
30	

It is made available under a CC-BY 4.0 International license .

31 Abstract:

The clinical course and severity of COVID-19 vary among patients. This study aimed to 32 33 investigate the association of the interferon receptor (IFNAR2) rs2236757 and oligoadenylate 34 synthetase 3 (OAS3) rs10735079 gene polymorphisms with risk of COVID-19 infection and 35 severity among Palestinian patients. The study was conducted between April and May 2021 on 36 154 participants that divided into three groups: the control group (RT-PCR-negative, n=52), the 37 community cases group (RT-PCR-positive, n = 70) and the critically ill cases (ICU group; n = 32). 38 Genotyping of the studied polymorphisms was conducted by amplicon-based next-generation 39 sequencing.

40 The genotype distribution of the *IFNAR2* rs2236757 was significantly different among the study 41 groups (P = 0.001), while no significant differences were observed in the distribution of OAS3 rs10735079 genotypes (P = 0.091). Logistic regression analysis adjusted for possible 42 43 confounding factors revealed a significant association between the risk allele rs2236757A and 44 critical COVID-19 illness (P < 0.025). Among all patients, the rs2236757GA carriers were more 45 likely to have sore throat (OR, 2.52 (95% CI 1.02-6.24); P = 0.011); the risk allele rs2236757A was associated with dyspnea (OR, 4.70 (95% CI 1.80-12.27); P < 0.001), while the rs10735079A 46 carriers were less prone to develop muscle aches (OR, 0.34 (95% CI 0.13-0.88); P = 0.0248) and 47 48 sore throat (OR, 0.17 (95% CI 0.05-0.55); P < 0.001). In conclusion, our results revealed that the 49 rs2236757A variant was associated with critical COVID-19 illness and dyspnea, whereas the rs10735079A variant was protective for muscle aches and sore throat. 50

51

52 **Key Words**: SARS-CoV-2; COVID-19; SNPs; *OAS3*; *IFNAR2*.

It is made available under a CC-BY 4.0 International license .

54 Introduction

55 The Coronavirus disease 2019 (COVID-19) is a respiratory and systemic disease caused by 56 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China, 57 in December 2019 and then rapidly spread across the globe. Worldwide, more than 613 million 58 coronavirus patient was reported with more than 6.5 million of total deaths (Worldometers.info: 59 Dover, Delaware, U.S.A) accessed date 10-09-2022). It is transmitted predominately from person 60 to person mainly through inhalation of small, exhaled respiratory droplets containing infectious 61 virions [1]. The clinical manifestations range from asymptomatic, to severe, life-threatening 62 acute respiratory distress syndrome (ARDS), multi-organ failure, and death [2]. The major 63 symptoms of the disease include fever, cough, fatigue, sore throat, headache, and shortness of 64 breath, with progression to pneumonia [3]. Households are favorable venues for viral 65 transmission, where family members may crowd and be in close contact without following social 66 distancing rules or using masks. Although all household contacts of a positive COVID-19 patient 67 are exposed to the virus, not all get infected.

Previous reports showed that male gender, elder age group, and the existence of comorbidities (e.g., cardiovascular, pulmonary, and renal diseases) are risk factors for COVID-19 infection [4]. However, the wide range of the reported symptoms suggested that genetic risk factors may also have a crucial role in disease progression. Although the virus's new mutations have emerged (e.g., UK, South Africa, and India), few studies described the inter-individual genetic differences in the immune response to these new versions of coronavirus.

74 It was reported that variants of the angiotensin converting enzyme 2 (ACE2) gene encode the 75 cellular receptor for SARS-CoV-2 and polymorphisms of serine protease TMPRSS2 affect viral 76 entry and invasion and thus increase COVID-19 severity [5,6]. Moreover, a genome-wide 77 association study (GWAS) conducted in the UK compared the genetic variants in critically ill patients (n= 2244) with severe COVID-19 to variants found in a healthy control group. The study 78 79 revealed significant associations between the severity of COVID-19 and the genetic variants in 80 five loci including chromosome 3p21.31, spanning the SLC6A20, LZTFL1, CCR9, FYCO1, 81 CXCR6, and XCR1 genes; chromosome 12q24.13, in the OAS gene cluster; chromosome 82 19p13.2, near tyrosine kinase 2 (TYK2); chromosome 19p13.3, within dipeptidyl peptidase 9 83 (DPP9); chromosome 21g22.1, within the interferon receptor gene INFAR2. Of these genes,

It is made available under a CC-BY 4.0 International license .

84 *IFNAR2* and *OAS*, are important in the early stages of the disease, whereas the *DPP9*, *TYK2*, and

85 *CCR2* genes drive inflammatory processes in the late stages of critical COVID-19 [7].

86 . It is well-established that SARS-CoV-2 infection activates innate and adaptive immune
87 response, failure of this system and dysregulated massive pro-inflammatory host response would
88 cause harmful tissue damage [8].

In this context, the study objective was to investigate the association of four SNPs (*IFNAR2* rs2236757, *DPP9* rs2109069, *OAS3* rs10735079, and *LZTFL1* rs73064425 variants), with the susceptibility to COVID-19 infection in Palestinian household contacts and their associations with the clinical manifestations and severity of COVID 19, using amplicon-based next generation sequencing (NGS).

94

95 Materials and methods

96 Study participants

97 The study participants were recruited from 30 household Palestinian families- living in different 98 cities in the West Bank, Palestine- between April and May 2021. The family was included in the 99 study if it has at least one clinically and laboratory-confirmed COVID-19 case and one 100 laboratory-negative household contact with no COVID-19 symptoms. We divided all family 101 members into two groups: infected cases (community cases group) or uninfected household 102 contacts (control group). An infected case was defined by having a positive RT-PCR test 103 regardless of having symptoms or not and regardless of being a primary or secondary case. An 104 uninfected contact was defined as a family member who had unprotected contact with a positive 105 case, lives at the same place, stayed asymptomatic for ten days after symptoms onset or RT-PCR 106 diagnosis of a positive case; and was tested negative by RT-PCR. Additionally, we consecutively 107 enrolled patients from an intensive care unit (ICU) -at the Palestinian Medical Complex. 108 Ramallah - due to critical COVID-19 illness (ICU cases).

We excluded individuals who received COVID-19 vaccination, regardless of the type of the vaccine. Patients' data, including demographic information, symptoms, RT-PCR test result, and comorbidities, were collected via a well-structured questionnaire supervised by health care personnel.

- 113
- 114

It is made available under a CC-BY 4.0 International license .

115 Sampling, DNA extraction, and genotyping

Blood-sample (five ml) was collected in an EDTA tube from all study participants. The DNA 116 117 was extracted from each blood sample (200 µl) using a genomic QIAamp DNA purification kit 118 as per the manufacturer's instructions (Qiagen, Hilden, Germany) and kept frozen (-20C) for 119 further analysis. All DNA samples were genotyped for the rs2236757 of IFNAR2, rs2109069 of DPP9, rs10735079 of OAS3, and rs73064425 of the LZTFL1 gene using amplicon-based NGS 120 121 (NGS). Briefly, two primers (forward and reverse) were used to target each single nucleotide 122 polymorphism (SNP) as described in Table S1. All primers were modified with over-hanged 123 Illumina adaptor sequences at the 5' ends (bolded, Table S1), targeting partial sequences of the 124 studied genes. The final product size for each targeted gene was mentioned in Table S1.

125 The PCR product was visualized by 1.5% agarose gel, cleaned by Agencourt AMPure XP system 126 (X1, A63881; Beckman Coulter Genomics, Indianapolis, IN, USA), and eluted into a final 127 volume of 25 µl. All purified samples were amplified by dual indices PCR to barcode each sample using Nextera XT Index Kit (Illumina, San Diego, CA, USA); Five µl from each 128 129 barcoded sample were pooled together, cleaned again by Agencourt AMPure XP system (X1), 130 and eluted in 50 μ l elution buffer. The concentrations of the prepared Libraries were tested by 131 Qubit® Fluorometer (Invitrogen, Carlsbad, CA, USA). A concentration of 4 nM was used with a 132 target of 20k reads for each sample. Deep sequencing was done by NextSeq 500/550 machine 133 using 150-cycle Mid Output Kit (Illumina, San Diego, CA, USA).

134

135 **Bioinformatics and Sequence Analysis**

The sequencing data were uploaded to the Galaxy web platform, and we used the public server at "usegalaxy.org" to analyze the obtained DNA sequences [9]. The workflow of filtration included Illumina adaptor trim and quality selection of Q > 20 with a minimal read length of 100 bp. We used eight virtual probe sequences to identify the targeted variants (Table S1). Ultimately, the genotypes were determined based on the ratio between the read counts for wild-type and minor alleles. SNPs were included in the study if they passed our quality measures; Hardy–Weinberg equilibrium (HWE) > 0.05 and genotyping rate > 95%.

143

144

It is made available under a CC-BY 4.0 International license .

146 Statistical Analysis

147 We performed the statistical analysis using the SPSS package, version 26.0 (SPSS, Inc., 148 Chicago, IL, USA) and the R environment v.4.1.3. All tests were two-tailed, and we considered 149 P-value < 0.05 significant unless specified. We tested for The Hardy-Weinberg equilibrium 150 (HWE) for all SNPs using the "SNPassoc" package [10]. Moreover, we examined the genetic susceptibility of SARS-CoV-2 and the genetic association with the critical COVID-19 illness by 151 152 comparing the community patients with the controls, and the ICU patients with the controls, 153 respectively, using five genetic models (co-dominant, dominant, over-dominant, recessive, and 154 additive). Models were adjusted for patient characteristics; age, gender, smoking, history, hypertension, diabetes mellitus, and coronary artery diseases using the "SNPassoc" package. 155 156 Adjusted odds ratios (ORs) with the associated 95% confidence interval (CI) were calculated for 157 each model. The same models were used to investigate Gene-(Symptoms/Signs) associations. 158 The best model for each SNP was selected using the Akaike information criterion [11]. We used Bonferroni correction for multiple comparisons to correct statistical significance (P < 0.05, 159 160 divided by the number of analyzed SNPs) [12,13]. Ultimately, we investigated for any potential 161 gene-gene interaction.

162

163 **Results**

164 Characteristics of Study Participants

165 A total of 154 Palestinians were included in this study and divided into three groups; COVID-19 166 infected patients (Community cases group, n=70), uninfected household contacts (Control group, 167 n=52) and critically ill COVID -19 patients (ICU group, n=32). In each group, the median (IOR) 168 age was 28 (27), 24.5 (21.5), and 61 years (27). The characteristics and comorbidities of each 169 study group are shown in Table 1. The median age, the prevalence of smoking, diabetes mellitus 170 (DM), hypertension, and coronary artery disease (CAD) were significantly higher in the ICU 171 group (P < 0.05). The clinical characteristics of COVID-19 patients in the community and ICU 172 groups with signs and symptoms frequencies are presented in Table 2. The percentage of 173 symptomatic patients was 93% in the community cases group, whereas 100% in the ICU group. 174 The frequency of fatigability, headache, and loss of taste and/ or smell was significantly higher 175 in the community cases group (P < 0.05). However, dyspnea and cough were more frequent in 176 the ICU group (P < 0.05).

It is made available under a CC-BY 4.0 International license .

177 Genotyping of *IFNAR2* rs2236757 and *OAS3* rs10735079

178 The minor allele frequency (MAF) of the IFNAR2 rs2236757A and the OAS3 rs10735079A was 179 27% and 50%, respectively. The frequency and genotypes distribution of the IFNAR2 180 rs2236757A and the OAS3 rs10735079A among the three study groups are provided in Table 3. 181 The IFNAR2 rs2236757 genotypes distribution was significantly variable among the study 182 groups (P = 0.001), while no significant differences were observed in the distribution of OAS3 183 rs10735079 genotypes (P = 0.091). The two SNPs; DPP9 rs2109069, and the LZTFL1 184 rs73064425, were excluded from the study due to deviation from the HWE (i.e., P < 0.05) and 185 the low genotyping rate (i.e., <95%).

- 186 187
- *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms and susceptibility to COVID-19
 infection

190 Logistic regression analysis under five genetic models adjusted for age, sex, smoking history, 191 DM, hypertension, and CAD was used to investigate the role of *IFNAR2* rs2236757 and *OAS3* 192 rs10735079 polymorphisms in the susceptibility of COVID-19 infection and severity, the 193 community cases group was compared to the control group and the ICU group was compared to 194 the control group. As shown in Table 4, none of the studied polymorphisms have a statistically 195 significant association with SARS-CoV-2 infection among community cases (P > 0.025) after 196 Bonferroni correction. However, the risk allele rs2236757A of the IFNAR2 gene was 197 significantly associated with critical COVID-19 illness in all genetic models (P < 0.025) except 198 for the recessive (P = 0.4). According to the Akaike information criterion, the dominant model 199 was the best to explain the association (OR, 8.65 (95% CI 1.60-46.68); P = 0.005). No 200 significant relationship between the OAS3 rs10735079 polymorphism and critical COVID-19 201 illness was observed (P > 0.025; Table S2).

202

Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms

Logistic regression analysis under five genetic models adjusted for age, sex, smoking history, DM, hypertension, and CAD was used to investigate the association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms.

It is made available under a CC-BY 4.0 International license .

208 For all patients (the community cases group and ICU group), the IFNAR2 rs2236757 GA carriers 209 were more likely to have a sore throat (OR, 2.52 (95% CI 951.02-6.24); P = 0.011) (Table 5). In 210 addition, patients who developed dyspnea were more likely to have the risk allele rs2236757A; 211 the association was best explained by the additive model (OR, 4.70 (95% CI 1.80-12.27); P <212 0.001). On the other hand, patients with the risk allele rs10735079A were less prone to develop muscle aches (OR, 0.34 (95% CI 0.13-0.88); P = 0.0248) and sore throat (OR, 0.17 (95% CI 213 214 (0.05-0.55); P < 0.001), both associations were best explained by the recessive model (Table 5). 215 Further analysis was performed to compare the community cases group with the control group 216 and the ICU group with the control group as shown in Table 6. None of the community cases 217 group was homozygous for the risk allele *IFNAR2* rs2236757A (Table 6). However, the risk 218 allele rs2236757A was associated with loss of taste or smell (OR, 3.57 (95% CI 1.19-10.72); P = 219 0.019), muscle aches (OR, 3.65 (95% CI 1.12-11.86); P = 0.025), and dyspnea (OR, 4.84 (95% 220 CI 1.45-16.13); P = 0.006). We also found that patients with sore throat in the community cases 221 group were unlikely to be homozygous (AA) for the risk allele rs10735079A of OAS3; the 222 association was only explained by the recessive model (OR, 0.19 (95% CI 0.05-0.79); P =223 0.012). Among the ICU group, muscle aches were the only symptoms that had a genetic 224 association; patients with the risk allele rs10735079A were less prone to muscle aches in two 225 models (recessive and additive), and best explained by the additive (OR, 0.22 (0.05-0.99); P = 226 0.014) (Table 6). We tested gene-gene interaction in all models that had a significant association 227 with the clinical manifestations; we did not find a statistically significant interaction between the 228 SNPs. Still, heterozygous rs2236757 (GA) carriers with sore throat were less likely to be 229 homozygous (AA) for the risk allele rs10735079A (OR, 0.06 (95% CI 0.01-0.57)) (data not 230 shown). 231

201

232

233

234

235

236

237

It is made available under a CC-BY 4.0 International license .

239 **Discussion**

240 COVID-19 manifestations are variable among patients, even amongst household members. 241 Before the introduction of the COVID-19 vaccination, 33% of people with SARS-CoV-2 242 infection were reported to be asymptomatic [14]. Wu Z and McGoogan JM reported mild COVID-19 infection in 81% of the patients, severe disease in 14%, and critical illness in 5%[15]. 243 244 Age, comorbidities, sex, and socioeconomic background play an essential role in COVID-19 245 severity [16-19]. Moreover, novel host genetic factors associated with COVID-19 infection and 246 severity were identified through the collaborated community of human genetics researchers [20]. 247 In the current study, we found that the risk allele IFNAR2 rs2236757A has a significant 248 association with the critical COVID-19 illness. Such an association was not present for the 249 rs10735079 variant. The rs2236757A variant was found to be related to the critical COVID-19 250 illness in genome-wide significant associations. Additionally, IFNAR2 has a causal role from a 251 Mendelian randomization result; increased expression of the interferon receptor subunit IFNAR2 252 reduced the odds of severe COVID-19 (P = 0.0043) [7]. Type 1 interferons bind IFNAR2, which 253 leads to activation and signal transduction, involving the JAK-STAT pathway [21]. 254 Consequently, this pathway initiates antiviral activity from the target cells and induces apoptosis 255 in infected cells [22]. The role of *IFNAR2* expression was further replicated in other Mendelian 256 randomization studies [23–25]. OAS is a family of antiviral proteins consisting of four members, 257 OAS1, OAS2, OAS3, and OAS-like protein [26]. Both, Interferon and virus infection stimulate 258 the transcription of OAS genes in the cell [27,28]. Ribonuclease L is activated through the 259 OAS1- to 3 proteins; products with 2'-5' oligoadenylate synthetase activity. Ribonuclease L 260 activation leads to the degradation of the cellular and viral RNA, resulting in the inhibition of 261 protein synthesis and terminating viral replication [29–31]. The variant rs10735079 lies in the 262 interferon-inducible OAS gene cluster (OAS1, OAS2, and OAS3) and was associated with critical COVID-19 illness (P = 1.65×10^8) in genome-wide significant associations [7]. However, a 263 264 similar association was not present in our study.

Different symptom clusters have a difference in in-hospital outcomes [32]. Reis et al. reported in a cross-sectional study with nearly 60,000 COVID-19 patients that fever and breathing difficulty increased the chances of hospitalization and death. However, running nose, sore throat, diarrhea, and headache were associated with lower odds of hospitalization and death; they concluded that these symptoms indicate a protective effect [33]. Sadeghifar et al. showed in their binary logistic

It is made available under a CC-BY 4.0 International license .

270 regression model of disease outcome by disease symptoms that shortness of breath and abnormal

271 chest radiographic findings were predictors of higher mortality. Conversely, patients with sore

- throats signified lower mortality [34]. Moreover, Chang et al. indicated that body temperature,
- 273 chills, initial chest X-ray findings, and the presence of diabetes were significant predictors of
- progression to the severe stage of COVID-19 [35].
- Studies that evaluate the role of human genetics in developing the different signs and symptoms of COVID-19 are scarce. Williams et al. studied 3261 same-sex twins to investigate the presence of heritable components in developing the different symptoms of COVID-19. They found heritability elements for delirium, diarrhea, fatigue, anosmia, and meal skipping [36].
- 279 Herein, we investigated the role of the rs2236757 and the rs10735079 variants in developing the 280 different signs and symptoms of COVID-19 in all COVID-19 patients, and in the community 281 patients and ICU patients, separately. Our results indicated that patients with the risk allele 282 rs2236757A were more likely to have dyspnea and sore throat. Among the community patients, 283 the risk allele rs2236757A was found to be associated with dyspnea, loss of taste or smell, and 284 muscle aches. Surprisingly, patients with the risk allele rs10735079A were unlikely to have a 285 sore throat or muscle aches; in particular, the community cases group was less likely to have a 286 sore throat, and the ICU subgroup was less prone to muscle aches. Given that the risk allele 287 rs10735079A was found to be associated with critical COVID-19 illness in multiple previous 288 studies [7,37], the inverse association of the risk allele rs10735079A with having a sore throat 289 might be consistent with Reis et al. and Sadeghifar et al. findings indicating that sore throat 290 might have a protective effect against COVID-19 hospitalization and death [33,34].
- 291 It was reported that Interferon-beta inhibits SARS-CoV-2 virus replication in vitro [38]. 292 However, clinical trials did not reveal a clear benefit from interferon therapy for hospitalized 293 patients with severe COVID-19 [39-42]. Yet, a systematic review of five clinical trials 294 concluded that early administration of Interferon-beta combined with other antiviral drugs is 295 promising [43]. Low expression of *IFNAR2* has a causal role in the progression to critical 296 COVID-19 illness [7]; our study was in line with the Pairo-Castineira et al. study which 297 demonstrated that rs2236757A was associated with the severity of COVID-19 illness [7]. 298 Therefore, a randomized controlled trial that examines the role of interferon therapy in COVID-299 19 patients who have the rs2236757A variant or other reported variants will help to understand 300 the role of interferon therapy and its benefits.

It is made available under a CC-BY 4.0 International license .

301 Our study is limited by the small number of included participants, which was in part due to the 302 newly emerged variants of the SARS-CoV-2 virus; we could not continue recruiting patients 303 when the new SARS-CoV-2 variants became prevalent in Palestine, as different variants may 304 have different manifestations and pathogenesis [44,45]. Moreover, the COVID-19 vaccination 305 was started by the government, which can alter the results. The limited number of patients in the 306 present study may explain the lack of association between the rs10735079 polymorphism and the 307 critical COVID-19 illness. Nonetheless, targeting families strengthen the certainty of adequate 308 exposure to the SARS-CoV-2 virus in the control group. Additionally, the present study is the 309 first in Palestine and one of the few studies that investigated the role of human genetic factors in 310 COVID-19 signs and symptoms. In Conclusion, our study revealed that the IFNAR2 rs2236757A 311 variant is associated with critical COVID-19 illness. the risk allele rs2236757A was associated with dyspnea and sore throat while patients with the risk allele rs10735079A were unlikely to 312 313 have a sore throat or muscle aches. Our study may provide preliminary results for further genetic association studies to clarify the role of human genetics in different signs and symptoms of 314 315 COVID-19 and to enhance our understanding of the pathophysiology of SARS-CoV-2 infection 316 and its complications.

317

318 Acknowledgements:

319 The authors would like to thank all the study participants

320

321 Authors' contributions:

322 SE and AN designed and supervised the experiments, edited and revised the manuscript. MA 323 analyzed the data and wrote the first draft of the manuscript. MA, OA, RA, RS, OM, TH, and ZE 324 extracted the DNA and performed the experiments. AJ involved in patient sampling and data 325 collection. All authors read and approved the final manuscript.

- 326 Funding
- 327 This research received no specific grant from any funding agency.
- 328 Availability of data and materials:
- 329 Data used in this research are available from the corresponding author on request
- 330
- 331

332 **Declarations**

333 Ethics approval and consent to participate

- 334 The study procedure was approved by the research ethics committee at Al-Quds University
- 335 (184/REC/2021), with implied consent from all participants.

336 Competing interests

- 337 The authors declare that no competing interests exist.
- 338

339 **References:**

- Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease
 (COVID-19) outbreak. J Autoimmun. 2020;109. doi:10.1016/J.JAUT.2020.102433
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395: 1033–1034. doi:10.1016/S0140-6736(20)30628-0
- 345
 3. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579: 270–273.
 347 doi:10.1038/S41586-020-2012-7
- 348
 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for 349 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 350 study. The Lancet. 2020;395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3/ATTACHMENT/E61DC4CE-2C32-4FA9-85D7-95911E7D3B94/MMC1.PDF
- Soft and Sof
- Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and
 expression as candidates to sex and country differences in COVID-19 severity in Italy.
 Aging. 2020;12: 10087–10098. doi:10.18632/AGING.103415
- Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al.
 Genetic mechanisms of critical illness in COVID-19. Nature 2020 591:7848. 2020;591:
 92–98. doi:10.1038/s41586-020-03065-y
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497–506. doi:10.1016/S0140-6736(20)30183-5
- Afgan E, Baker D, van den Beek M, Blankenberg D, Bouvier D, Čech M, et al. The
 Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016
 update. Nucleic Acids Res. 2016;44: W3–W10. doi:10.1093/NAR/GKW343
- 367 10. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X, et al. SNPassoc: an
 368 R package to perform whole genome association studies. Bioinformatics. 2007;23: 654–
 369 655. doi:10.1093/BIOINFORMATICS/BTM025
- Bozdogan H. Model selection and Akaike's Information Criterion (AIC): The general
 theory and its analytical extensions. Psychometrika 1987 52:3. 1987;52: 345–370.
 doi:10.1007/BF02294361

- 12. carboni CB-S in onore del professore salvatore ortu, 1935 undefined. Il calcolo delle
 assicurazioni su gruppi di teste. ci.nii.ac.jp. [cited 16 Jul 2022]. Available:
 https://ci.nii.ac.jp/naid/20001029336/
- Scienze CB-P del RIS di, 1936 undefined. Teoria statistica delle classi e calcolo delle
 probabilita. cir.nii.ac.jp. [cited 16 Jul 2022]. Available:
 https://cir.nii.ac.jp/crid/1570009749360424576
- 379 14. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic :
 380 A Systematic Review. Ann Intern Med. 2021;174: 655–662. doi:10.7326/M20-6976
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
 From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323: 1239–
 1242. doi:10.1001/JAMA.2020.2648
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
 severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:
 669–677. doi:10.1016/S1473-3099(20)30243-7
- Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, el Burai Felix S, et al.
 Coronavirus Disease 2019 Case Surveillance United States, January 22-May 30, 2020.
 MMWR Morb Mortal Wkly Rep. 2020;69: 759–765. doi:10.15585/MMWR.MM6924E2
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients
 Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323: 2052–2059.
 doi:10.1001/JAMA.2020.6775
- Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, et al. Disparities in COVID-19
 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and
 Meta-analysis. JAMA Netw Open. 2021;4.
- 398 doi:10.1001/JAMANETWORKOPEN.2021.34147
- Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. Mapping the
 human genetic architecture of COVID-19. Nature 2021 600:7889. 2021;600: 472–477.
 doi:10.1038/s41586-021-03767-x
- 402 21. Novick D, Cohen B, Rubinstein M. The human interferon $\alpha\beta$ receptor: Characterization 403 and molecular cloning. Cell. 1994;77: 391–400. doi:10.1016/0092-8674(94)90154-6
- Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a
 multimodal machinery of gene regulation by the IRF family of transcription factors. Curr
 Opin Immunol. 2002;14: 111–116. doi:10.1016/S0952-7915(01)00305-3
- 407 23. Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, et al.
 408 Actionable druggable genome-wide Mendelian randomization identifies repurposing
 409 opportunities for COVID-19. Nature Medicine 2021 27:4. 2021;27: 668–676.
 410 doi:10.1038/s41591-021-01310-z
- Liu D, Yang J, Feng B, Lu W, Zhao C, Li L. Mendelian randomization analysis identified
 genes pleiotropically associated with the risk and prognosis of COVID-19. Journal of
 Infection. 2021;82: 126–132. doi:10.1016/J.JINF.2020.11.031
- 414 25. Hernández Cordero AI, Li X, Milne S, Yang CX, Bossé Y, Joubert P, et al. Multi-omics
 415 highlights ABO plasma protein as a causal risk factor for COVID-19. Hum Genet.
 416 2021;140: 969–979. doi:10.1007/S00439-021-02264-5/FIGURES/3
- 417 26. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. Nat Rev Immunol.
 418 2008;8: 559–568. doi:10.1038/NRI2314

- 419 27. P B, M V, D P, M R, J C. Interferon-responsive regulatory elements in the promoter of the 420 human 2',5'-oligo(A) synthetase gene. Mol Cell Biol. 1987;7: 4498–4504. 421 doi:10.1128/MCB.7.12.4498-4504.1987 422 28. Melchjorsen J, Kristiansen H, Christiansen R, Rintahaka J, Matikainen S, Paludan SR, et 423 al. Differential regulation of the OASL and OAS1 genes in response to viral infections. J 424 Interferon Cytokine Res. 2009;29: 199-207. doi:10.1089/JIR.2008.0050 425 29. Baglioni C, Minks MA, Clercq E de. Structural requirements of polynucleotides for the 426 activation of (2' - 5')An polymerase and protein kinase. Nucleic Acids Res. 1981;9: 427 4939-4950. doi:10.1093/NAR/9.19.4939 428 30. Dong B, Silverman RH. A bipartite model of 2-5A-dependent RNase L. J Biol Chem. 429 1997;272: 22236-22242. doi:10.1074/JBC.272.35.22236 430 31. Clemens MJ, Williams BRG. Inhibition of cell-free protein synthesis by pppA2' p5' A2' 431 p5' A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell. 432 1978;13: 565-572. doi:10.1016/0092-8674(78)90329-X 433 Millar JE, Neyton L, Seth S, Dunning J, Merson L, Murthy S, et al. Distinct clinical 32. 434 symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 435 patients in the ISARIC-4C study. Scientific Reports 2022 12:1. 2022;12: 1–13. 436 doi:10.1038/s41598-022-08032-3 437 33. dos Reis EC, Rodrigues P, de Jesus TR, de Freitas Monteiro EL, Virtuoso Junior JS, 438 Bianchi L. Risk of hospitalization and mortality due to COVID-19 in people with obesity: 439 An analysis of data from a Brazilian state. PLoS One. 2022;17. 440 doi:10.1371/JOURNAL.PONE.0263723 441 34. Sadeghifar J, Jalilian H, Momeni K, Delam H, Sheleme T, Rashidi A, et al. Outcome 442 evaluation of COVID-19 infected patients by disease symptoms: a cross-sectional study in 443 Ilam Province, Iran. BMC Infect Dis. 2021;21: 1-5. doi:10.1186/S12879-021-06613-444 7/TABLES/4 445 35. Chang MC, Park YK, Kim BO, Park D, Risk factors for disease progression in COVID-19 446 patients. BMC Infect Dis. 2020;20: 1-6. doi:10.1186/S12879-020-05144-X/FIGURES/1 447 Williams FMK, Freidin MB, Mangino M, Couvreur S, Visconti A, Bowyer RCE, et al. 36. 448 Self-Reported Symptoms of COVID-19, Including Symptoms Most Predictive of SARS-449 CoV-2 Infection, Are Heritable. Twin Res Hum Genet. 2020;23: 316–321. 450 doi:10.1017/THG.2020.85 451 37. Niemi MEK, Karjalainen J, Liao RG, Neale BM, Daly M, Ganna A, et al. Mapping the 452 human genetic architecture of COVID-19. Nature 2021 600:7889. 2021;600: 472-477. 453 doi:10.1038/s41586-021-03767-x Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, et al. 454 38. 455 Interferon- β -1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro 456 When Administered After Virus Infection. J Infect Dis. 2020;222: 722-725. 457 doi:10.1093/INFDIS/JIAA350 458 39. H P, R P, AM H-R, MP P, V S, Q AK, et al. Repurposed Antiviral Drugs for Covid-19 -459 Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384: 497–511. 460 doi:10.1056/NEJMOA2023184 Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et 461 40. 462 al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment 463 of Severe COVID-19. Antimicrob Agents Chemother. 2020;64. doi:10.1128/AAC.01061-464 20
 - 14

It is made available under a CC-BY 4.0 International license .

- 465 41. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of
 466 interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults
 467 with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet
 468 Respir Med. 2021;9: 1365–1376. doi:10.1016/S2213-2600(21)00384-2
- 469 42. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and
 470 efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2
 471 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir
 472 Med. 2021;9: 196–206. doi:10.1016/S2213-2600(20)30511-7
- 473 43. Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19
 474 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn
- 475 Schmiedebergs Arch Pharmacol. 2021;394: 829–838. doi:10.1007/S00210-021-02061-X
- 476 44. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom
 477 prevalence, duration, and risk of hospital admission in individuals infected with SARS478 CoV-2 during periods of omicron and delta variant dominance: a prospective
- 479 observational study from the ZOE COVID Study. Lancet. 2022;399: 1618–1624.
 480 doi:10.1016/S0140-6736(22)00327-0
- 481 45. Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and
 482 decreased pathogenicity. Signal Transduction and Targeted Therapy 2022 7:1. 2022;7: 1–
 483 3. doi:10.1038/s41392-022-01009-8

It is made available under a CC-BY 4.0 International license .

	Community patients (N=70)	ICU patients (N=32)	Control (N=52)	P- Value
M: F	32:38	19:13	33:19	0.124
Age †	28 [21.5-48.5]	61 [41-68]	24.5 [20.25- 41.75]	<0.001*
Smoking	15.70%	31.30%	30.80%	0.117
DM	5.70%	25%	3.80%	0.009
Hypertension	4.30%	43.80%	3.80%	0.001
CAD	4.30%	40.60%	0%	0.001

Table 1: Baseline characteristics and comorbidities.

 \dagger Median [25th -75th percentile]. * P-value was obtained by Independent-Samples Kruskal-Wallis Test. P < 0.05 was considered significant. M, male; F, female; DM, diabetes mellitus; CAD, coronary artery disease; ICU, intensive care unit.

Table 2: Signs and symptoms of COVID-19 in the community cases and the intensive care unit groups

	Community group(70)	cases	ICU group(32)		P-value
	N	%	Ν	%	1 -value
Symptomatic	64	93	32	100	0.118
Runny nose	34	49	7	22	0.009
Fatigue	52	75	11	36	0.001
Headache	49	71	10	33	0.001
Fever	43	62	21	70	0.463
Loss of smell/ taste	45	65	12	40	0.02
Muscle ache	42	61	21	68	0.51
Diarrhea	24	35	6	19	0.119
Sore throat	27	39	9	30	0.385
Cough	33	49	22	71	0.037
Dyspnea	24	35	27	87	0.001

P < 0.05 was considered significant. ICU, intensive care unit.

It is made available under a CC-BY 4.0 International license .

Table 3:	Genotypes	distribution	of	the	IFNAR2	rs2236757	and	OAS3	rs10735079	among	the
studied gr	oups										

SNP	Alleles (major/minor)	Minor allele frequency N (%)	Genotypes	Community cases group	ICU group	Control group	P- value
			AA	0	6	2	
rs2236757 (IFNAR2)	G/A	83 (26.9)	GA	35	15	17	0.001
			GG	35	11	33	
			AA	20	11	12	
rs10735079 (OAS3)	G/A	153 (50.3)	GA	31	8	28	0.091
			GG	19	13	10	

Person's chi-squared test, P < 0.05 was considered significant.

Table 4: Association of	IFNAR2 rs2236757	' polymorphism	with COVID	-19 infection	among the
studied groups					

SNP	Genetic model	Control	Community cases	ICU	Community cases Vs. Controls: OR (95% CI); P- value	ICU group Vs. Control: OR (95% CI); P-value		
	Codominant							
	GG	33	35	11				
	GA	17	35	15	2.14 (0.92-4.94); 0.028	9.55 (1.53-59.47)		
	АА	2	0	6		6.41 (0.47-87.80); 0.019		
	Dominant							
rs2236757	GG	33	35	11				
(IFNAR2)	GA+AA	19	35	21	1.85 (0.82-4.19); 0.134	8.65 (1.60-46.68); 0.005 †		
	Recessive							
	GG+GA	50	70	26				
	AA	2	0	6	0; 0.049	2.64 (0.27-26.06); 0.401		
	Over-dominant							
	GG+AA	35	35	17	2.29 (1.00-5.26); 0.046	6.99 (1.26-38.86); 0.015		

It is made available under a CC-BY 4.0 International license .

GA	17	35	15		
Additive					
	52	70	32	1.44 (0.67-3.07); 0.342	3.92 (1.17-13.10); 0.015

 \dagger Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant.

Table 5: Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms in all patients

rs2236757 (<i>IFNAR2</i>)		Yes	No	OR (95% CI)	P-value	rs10735079 ((OAS3)	Yes	No	OR (95% CI)	P-value
	Codominant †						Codominant				
	GG	13	32				GG	15	17	0.88 (0.33-2.38)	
	GA	23	25	2.52 (1.02-6.24)	0.011		GA	17	20	0.16 (0.04-0.58)	0.004
	AA	0	6	0			АА	4	26		
	Dominant						Dominant				
	GG	13	32		0.124		GG	15	17	0.47 (0.10.1.16)	0.000
	GA+AA	23	31	1.98 (0.82-4.76)	0.124		GA+AA	21	46	0.47 (0.19-1.10)	0.099
Sore throat	Recessive					Sore throat	Recessive †				
	GG+GA	36	57	0	0.026		GG+GA	32	37		< 0.001
	АА	0	6	0	0.020		АА	4	26	0.17 (0.05-0.55)	< 0.001
	Over-dominant						Over-dominant				
	GG+AA	13	38		0.019		GG+AA	19	43		0.162
	GA	23	25	2.89 (1.18-7.13)	0.018		GA	17	20	1.86 (0.78-4.45)	0.162
	Log-Additive						Log-Additive				
		36	63	1.25 (0.61-2.57)	0.538			36	63	0.44 (0.24-0.79)	0.004

medRxiv preprint doi: https://doi.org/10.1101/2022.09.27.22280425; this version posted September 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Codominant Codominant GG 16 29 GG 22 10 GA 29 20 4.28 (1.57-11.71) 0.002 GA 27 11 1.11 (0.38-3.22) 0.079 14 0.36 (0.12-1.09) AA 6 0 0 AA 16 Dominant Dominant GG GG 16 29 22 10 0.001 0.394 GA+AA 35 20 4.81 (1.77-13.09) GA+AA 41 27 0.67 (0.26-1.70)

Muscle

aches

0.054

0.009

< 0.001

Recessive †

Over-dominant

Log-Additive

49

14

36

27

63

21

16

26

11

37

0.34 (0.13-0.88)

1.81 (0.74-4.47)

0.60 (0.34-1.05)

0.0248

0.191

0.068

GG+GA

GG+AA

AA

GA

Recessive

GG+GA

GG+AA

Over-dominant

Log-Additive †

AA

GA

45

6

22

29

51

49

0

29

20

49

0

3.49 (1.32-9.25)

4.70 (1.80-12.27)

Dyspnea

 \dagger Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant

Table 6: Association of *IFNAR2* rs2236757 and *OAS3* rs10735079 polymorphisms with COVID-19 signs and symptoms in the community patients and ICU patients, separately

				Yes	No	OR (95% CI)	P-value
			Codominant				
		Loss of taste/smell	GG	18	17		
			GA	27	7	3.57 (1.19-10.72)	0.019
			AA	0	0		
			Codominant				
	rs2236757	Musala aabas	GG	17	18		
	(IFNAR2)	Muscle aches	GA	25	9	3.65 (1.12-11.86)	0.0254
Community patients			AA	0	0		
•			Codominant				
		Dyannaa	GG	8	27		0.006
		Dyspitea	GA	16	18	4.84 (1.45-16.13)	
			AA	0	0		
			Codominant				
	rs10735079	Sara threat	GG	9	10		
	(OAS3)	Sole initiat	GA	15	15	1.13 (0.33-3.89)	0.042
			AA	3	17	0.21 (0.04-1.01)	

It is made available under a CC-BY 4.0 International license .

			Dominant				
			GG	9	10		0.409
			GA+AA	18	32	0.62 (0.20-1.93)	0.408
			Recessive †				
			GG+GA	24	25		0.012
			AA	3	17	0.19 (0.05-0.79)	0.012
			Over-dominant				
			GG+AA	12	27		0.142
			GA	15	15	2.21 (0.76-6.45)	0.143
			Log-Additive				
				27	42	0.50 (0.24-1.02)	0.051
				Yes	No	OR (95% CI)	P-value
			Codominant				
			GG	11	2	0.26 (0.01-5.08)	
			GA	6	2		0.042
			AA	4	6	0.03 (0.00-1.00)	
			Dominant				
			GG	11	2	0.11(0.01-1.41)	0.046
ICU nationts			GA+AA	10	8	0.11 (0.01-1.41)	0.040
ice patients	rs10735079 (<i>OAS3</i>)	Muscle aches	Recessive				
			GG+GA	17	4		0.023
					~	0.11(0.01-0.91)	0.023
			AA	4	6	0.11 (0.01 0.91)	
			AA Over-dominant	4	6	0.11 (0.01 0.91)	
			AA Over-dominant GG+AA	4	8	0.11 (0.01 0.91)	0.698
			AA Over-dominant GG+AA GA	4 15 6	8 2	1.48 (0.20-10.84)	0.698
			AA Over-dominant GG+AA GA Log-Additive †	4 15 6	8 2	1.48 (0.20-10.84)	0.698

 \dagger Best model to explain the association according to the Akaike information criterion. The odds ratios and the P values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction a P-value < 0.025 was considered significant.